Μargarita Papatheodoridi

Corrigendum to ‘Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort’ [JHEP Reports (2026) 19;8(8):101898]

Sabela Lens, Habiba Kamal, Arno Furquim d’Almeida, Sara Battistella et autres

It has come to our attention that the incorrect author name “Victor de Ledhinghen” was published. The correct spelling is “Victor de Ledinghen.” This has been corrected in the online version of the article. The authors apologize for any inconvenience caused.

se, es, be, it, fr, gr (code pays fourni par la source)

Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results from the PAGE-B cohort

George Papatheodoridis, George Ν. Dalekos, Ramazan Idılman, Vana Sypsa et autres

BACKGROUND & AIMS: Long-term outcome data in patients with chronic hepatitis B (CHB) treated with high-genetic-barrier nucleos(t)ide analogues (NAs) beyond year 10 are scarce. We assessed the incidence and predictors of hepatocellular carcinoma (HCC), liver transplantation (LT), all-cause and liver-related death, and …

gr, tr, es, nl, it (code pays fourni par la source)

From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management

Monica Radu, Μargarita Papatheodoridi, Habiba Kamal, Sabela Lens et autres

Hepatitis delta virus (HDV) infection causes chronic hepatitis D (CHD), the most severe form of chronic viral hepatitis with a high risk of progression to advanced liver disease. Off-label pegylated interferon alpha was the primary treatment option in Europe prior to the …

ro, gr, gb, se, es, us, it, de (code pays fourni par la source)

HERACLIS_BLV_D: Adherence to Real‐Life Therapy With Bulevirtide in Chronic Hepatitis D

Dimitra Lakiotaki, Μargarita Papatheodoridi, Vasilios Sevastianos, Kalliopi Zachou et autres

and biochemical response (BR) as normal ALT (≤ 40 IU/L). Adherence was evaluated through the national prescription system based on executed monthly BLV prescriptions. Treatment discontinuation was defined as no executed BLV prescription for > 3 months at the end of follow-up. …

gr (code pays fourni par la source)

Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort

Sabela Lens, Habiba Kamal, Arno Furquim d’Almeida, Sara Battistella et autres

BACKGROUND & AIMS: Hepatitis delta virus (HDV) is the most aggressive form of chronic viral hepatitis. As new therapies emerge, a clearer understanding of its natural history - particularly in early disease stages - is needed. We assessed real-world outcomes of HDV-infected …

se, es, be, it, fr, gr (code pays fourni par la source)

OS-070-YI Peg-IFN add-on versus nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B – a pooled analysis of two global cohorts (RETRACT-B and PROSPER studies)

Edo J. Dongelmans, Grishma Hirode, Florian van Bömmel, Rachel Wen-Juei Jeng et autres

OS-068-YI The new EASL treatment indications for HBeAg-negative chronic hepatitis B virus infection reduce grey-zone patients and reflect better routine clinical practice

Μargarita Papatheodoridi, Sofia Paraskevopoulou, Panagiota Ioannidou, Paraskevi Fytili et autres

TOP-582 Bulevirtide monotherapy prevents liver decompensation in patients with hdv-related cirrhosis: a case control study with propensity score weighted analysis

Elisabetta Degasperi, Annalisa De Silvestri, Dominique Roulot, Maria Paola Anolli et autres

SAT-560 Prevalence and clinical relevance of cardiometaboloc factors in european patients with HDV-related liver disease (methdv study) - a save-d and d-shield pooled analysis

Maria Paola Anolli, Elisabetta Degasperi, Liana Gheorghe, Alessandro Loglio et autres

THU-172 Eligibility for resmetirom or semaglutide therapy in a real-life Greek cohort of patients with metabolic associated steatotic liver disease

Μargarita Papatheodoridi, Antonia Neonaki, Alexandra Argyrou, Stratigoula Sakellariou et autres

FRI-585-YI Performances of the page-b and amap scores to predict hepatocellular carcinoma in patients with compensated delta cirrhosis treated long-term with bulevirtide monotherapy (save-d study)

Maria Paola Anolli, Elisabetta Degasperi, Dana Sambarino, Marta Borghi et autres

OS-066 Long-term virological and clinical outcomes in patients with hdv-related cirrhosis treated with bulevirtide monotherapy for up to 4 years (save-d study)

Elisabetta Degasperi, Maria Paola Anolli, Dana Sambarino, Marta Borghi et autres